venBio Partners LLC Invests $160.57 Billion in Pharvaris N.V. $PHVS

venBio Partners LLC purchased a new stake in Pharvaris N.V. (NASDAQ:PHVS) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,643,430 shares of the company’s stock, valued at approximately $160,569,809,000. Pharvaris comprises about 30.9% of venBio Partners LLC’s holdings, making the stock its biggest holding. venBio Partners LLC owned approximately 7.10% of Pharvaris as of its most recent SEC filing.

Several other large investors have also bought and sold shares of PHVS. Seven Fleet Capital Management LP raised its stake in shares of Pharvaris by 472.3% during the 1st quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock worth $8,947,000 after purchasing an additional 261,355 shares during the period. DV Trading LLC bought a new position in Pharvaris during the first quarter valued at about $4,067,000. PSP Research LLC bought a new position in Pharvaris during the fourth quarter valued at about $569,000. ADAR1 Capital Management LLC purchased a new stake in Pharvaris during the second quarter worth about $3,649,000. Finally, 5AM Venture Management LLC purchased a new stake in Pharvaris during the second quarter worth about $27,581,008,000.

Insider Activity at Pharvaris

In other Pharvaris news, insider Anna Nijdam sold 2,670 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $30.87, for a total transaction of $82,422.90. Following the transaction, the insider directly owned 46,275 shares in the company, valued at $1,428,509.25. This trade represents a 5.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Berndt Modig sold 2,292 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $34.77, for a total transaction of $79,692.84. Following the transaction, the chief executive officer directly owned 130,625 shares in the company, valued at approximately $4,541,831.25. This represents a 1.72% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 121,325 shares of company stock valued at $4,270,425. Company insiders own 11.84% of the company’s stock.

Wall Street Analysts Forecast Growth

PHVS has been the subject of several research analyst reports. Wall Street Zen lowered shares of Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. Royal Bank Of Canada increased their price objective on Pharvaris from $51.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. Citizens Jmp raised their target price on Pharvaris from $74.00 to $75.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 13th. Finally, Wells Fargo & Company assumed coverage on Pharvaris in a research note on Wednesday, July 15th. They issued an “overweight” rating and a $55.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $51.08.

Pharvaris Price Performance

NASDAQ PHVS opened at $37.00 on Friday. The company’s 50 day simple moving average is $34.56 and its two-hundred day simple moving average is $30.71. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $38.13. The stock has a market capitalization of $2.42 billion, a PE ratio of -12.13 and a beta of -2.31.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, research analysts anticipate that Pharvaris N.V. will post -3.15 EPS for the current year.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.